• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

Physicians Assess Injectable

Article

Toronto - A group of Canadian physicians who use Artecoll, an injectable currently awaiting FDA approval, is calling for the development of formal clinical guidelines and further research to help avoid adverse patient reactions.

Recent Videos
Related Content
April Armstrong, MD, MPH, Shares Insights on the NPF's Psoriasis Health Indicator Report

April Armstrong, MD, MPH, Shares Insights on the NPF's Psoriasis Health Indicator Report

Article
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients

The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients

Podcast
Definitions and Diagnostic Criteria of Generalized Pustular Psoriasis Require Continuity, Accuracy, Researchers Report

Definitions and Diagnostic Criteria of Generalized Pustular Psoriasis Require Continuity, Accuracy, Researchers Report

Article
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis

The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis

Podcast
Finger-to-Palm Distance Among Potential Indicators of Skin Thickening, Early-Onset Systemic Sclerosis

Finger-to-Palm Distance Among Potential Indicators of Skin Thickening, Early-Onset Systemic Sclerosis

Article
BD2-Selective BET Inhibitor VYN202 Demonstrates Positive Safety and Tolerability in Phase 1a Trial

BD2-Selective BET Inhibitor VYN202 Demonstrates Positive Safety and Tolerability in Phase 1a Trial

Article
© 2024 MJH Life Sciences

All rights reserved.